{
    "eid": "2-s2.0-85081667499",
    "title": "Molecular approaches to allergen-specific immunotherapy: Are we so far from clinical implementation?",
    "cover-date": "2020-05-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [
        "allergen-specific immunotherapy",
        "blocking antibodies",
        "clinical trial",
        "efficacy",
        "hypoallergenic",
        "recombinant derivatives",
        "safety",
        "Treg"
    ],
    "authors": [
        "Phornsiri Pechsrichuang",
        "Alain Jacquet"
    ],
    "citedby-count": 14,
    "ref-count": 105,
    "ref-list": [
        "Immunotherapy: What lies beyond",
        "EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy",
        "Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers",
        "Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization",
        "Pollen-derived nonallergenic substances enhance Th2-induced IgE production in B cells",
        "Proteolytic, lipidergic and polysaccharide molecular recognition shape innate responses to house dust mite allergens",
        "Allergen extracts for in vivo diagnosis and treatment of allergy: Is there a future?",
        "Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report",
        "Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark",
        "Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?",
        "Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis",
        "Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients",
        "Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen\u2013related apple allergy",
        "Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom",
        "Treatment with grass allergen peptides improves symptoms of grass pollen\u2013induced allergic rhinoconjunctivitis",
        "Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects",
        "Persistent treatment effect achieved at one year after four doses of Der p derived synthetic peptide immuno-regulatory epitopes in an exposure chamber model of house dust mite allergy",
        "Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1 derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study",
        "Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial",
        "A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy",
        "Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial",
        "Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy",
        "Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy",
        "Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32",
        "Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells",
        "Modified Allergens for immunotherapy",
        "Quality requirements for allergen extracts and allergoids for allergen immunotherapy",
        "Perspectives in allergen-specific immunotherapy: molecular evolution of peptide- and protein-based strategies",
        "Vaccination with genetically engineered allergens prevents progression of allergic disease",
        "Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives",
        "Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms",
        "Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial",
        "A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy",
        "DNA and mRNA vaccination against allergies",
        "Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study",
        "Prophylactic mRNA vaccination against allergy confers long-term memory responses and persistent protection in mice",
        "mRNA vaccines - a new era in vaccinology",
        "Virus-like particles as carrier systems to enhance immunomodulation in allergen immunotherapy",
        "Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies",
        "Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases",
        "Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies",
        "Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells",
        "Virus like particles displaying major HDM allergen Der p 2 for prophylactic allergen immunotherapy",
        "Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens",
        "Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults",
        "Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial",
        "Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study",
        "The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma",
        "Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects",
        "Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses",
        "Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines",
        "Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy",
        "Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections",
        "IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Fel d1 in human",
        "Intralymphatic Immunotherapy: Update and Unmet Needs",
        "Epicutaneous allergen administration: Is this the future of allergen-specific immunotherapy?",
        "Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts",
        "Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: A review of the literature",
        "Safety and efficacy of epicutaneous immunotherapy for food allergy",
        "Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults",
        "Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial",
        "Epicutaneous immunotherapy for peanut allergy modifies IgG4 responses to major peanut allergens",
        "Delivery of allergen powder for safe and effective epicutaneous immunotherapy",
        "State-of-the-art in marketed adjuvants and formulations in allergen immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)",
        "Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells",
        "Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy",
        "A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy",
        "EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis",
        "Pollinex Quattro: An innovative four injections immunotherapy in allergic rhinitis",
        "Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: A phase I/IIa study",
        "Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen",
        "Vitamin A and D in allergy: from experimental animal models and cellular studies to human disease",
        "Immunotherapy of allergic diseases using probiotics or recombinant probiotics",
        "Administration of a probiotic with peanut oral immunotherapy: a randomized trial",
        "PPOIT Study Team. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial",
        "The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis",
        "Effect of Lactobacillus rhamnosus GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy",
        "Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity",
        "Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis",
        "A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy",
        "Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo",
        "Fusion proteins of flagellin and the major birch pollen allergen Bet v 1 show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity",
        "Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1",
        "Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products",
        "Bystander immunotherapy as a strategy to control allergen-driven airway inflammation",
        "Induction of bystander tolerance and immune deviation after Fel d 1 peptide immunotherapy",
        "Recent developments and highlights in immune monitoring of allergen immunotherapy",
        "Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy",
        "Functional and immunoreactive levels of IgG4 correlate with clinical responses during the maintenance phase of house dust mite immunotherapy",
        "Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement",
        "Evolution of the IgE and IgG repertoire to a comprehensive array of allergen molecules in the first decade of life",
        "Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life",
        "Recombinant allergens for immunotherapy: state of the art",
        "Maternal allergen-specific IgG might protect the child against allergic sensitization",
        "Allergen-specific immunotherapy with recombinant grass pollen allergens",
        "Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study",
        "Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1",
        "Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial",
        "Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: The clinical benefits of treatment with Amb a 1 derived T cell epitopes",
        "Safety and tolerability of escalating doses of house dust mite- peptide antigen desensitization (HDM-PAD)",
        "Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Chulalongkorn Academic Advancement",
        "PERDO",
        "Ratchadapisek Sompotch Fund",
        "S&T Postgraduate Education and Research Development Office",
        "Chulalongkorn University",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}